About one in eight U.S. women will develop invasive breast cancer over the course of her lifetime, but there is some good news when it comes to treatment. Dr. Stephanie Graff shares the details about Atezolizumab, a type of immunotherapy, which has been approved for first line triple negative metastatic breast cancer. This is the first time immunotherapy has worked in such a difficult to treat cancer, and is a huge step forward for these breast cancer patients. Sarah Cannon Cancer Institute at HCA Midwest Health was pleased to have participated in this trial, with several area patients area showing positive results.
Overland Park Regional Medical Center March 22, 2019